180 Life Sciences (NASDAQ:ATNF) Given “Sell (E+)” Rating at Weiss Ratings

180 Life Sciences (NASDAQ:ATNF)‘s stock had its “sell (e+)” rating reaffirmed by research analysts at Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.

180 Life Sciences Trading Down 4.5 %

NASDAQ:ATNF opened at $1.28 on Wednesday. 180 Life Sciences has a 12 month low of $1.16 and a 12 month high of $17.75. The business’s 50-day moving average is $1.66 and its 200 day moving average is $2.12.

Institutional Investors Weigh In On 180 Life Sciences

A hedge fund recently bought a new stake in 180 Life Sciences stock. Anson Funds Management LP bought a new stake in shares of 180 Life Sciences Corp. (NASDAQ:ATNF) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 225,271 shares of the company’s stock, valued at approximately $410,000. Anson Funds Management LP owned about 7.08% of 180 Life Sciences as of its most recent filing with the Securities & Exchange Commission. 4.07% of the stock is owned by hedge funds and other institutional investors.

About 180 Life Sciences

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.